Multicenter Antimicrobial Resistance Surveillance of Clinical Isolates from Major Hospitals — China, 2022
Yan Guo, Li Ding, Yang Yang, Renru Han, Dandan Yin, Shi Wu, Demei Zhu, Fupin Hu
Abstract
<abstract abstract-type="Summary"> <sec> <b>What is already known about this topic?</b> Bacterial resistance surveillance is crucial for monitoring and understanding the trends and spread of drug-resistant bacteria. </sec><sec> <b>What is added by this report?</b> The number of strains collected in 2022 increased compared to 2021. The top five bacteria, including <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, <i>Staphylococcus aureus</i>, <i>Pseudomonas aeruginosa</i>, and Acinetobacter baumannii, remained largely unchanged. The detection rate of methicillin-resistant strains continued to decrease. Among clinical <i>Enterobacterales</i> isolates, the resistance rate to carbapenems was generally below 13%, except for <i>Klebsiella </i>spp., which had a resistance range of 20.4% to 21.9%. Most clinical <i>Enterobacterales</i> isolates were highly susceptible to tigecycline, colistin, and polymyxin B, with resistance rates ranging from 0.1% to 12.6%. The detection rate of meropenem-resistant <i>P. aeruginosa</i> and meropenem-resistant <i>Acinetobacter baumannii</i> showed a decreasing trend for the fourth consecutive year. </sec><sec> <b>What are the implications for public health practice?</b> Multidrug-resistant bacteria remain a significant public health challenge in clinical antimicrobial treatment. To effectively address bacterial resistance, it is essential to enhance both bacterial resistance surveillance and the prudent use of antimicrobial agents. </sec>